NT-175 by Neogene Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NT-175 overview

NT-175 is under development for the treatment of non-small cell lung cancer, head and neck squamous cell carcinoma, metastatic colorectal carcinoma, metastatic adenocarcinoma of pancreas, metastatic breast cancer, and other solid tumors. The therapeutic candidate comprises autologous T-cells genetically engineered to express HLA-A*02:01-restricted T cell receptor (TCR) targeting cells expressing TP53 R175H. It is administered through intravenous route.

Neogene Therapeutics overview

Neogene Therapeutics, Inc (Neogene Therapeutics), a subsidiary of Neogene Therapeutics BV, operates as pre-clinical stage biotechnology company. Neogene Therapeutics is headquartered in Santa Monica, California, the US.

For a complete picture of NT-175’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.